Jeff Yass’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-194,600
| Closed | -$1.76M | – | 14203 |
|
|
2025
Q4 | $1.76M | Buy |
194,600
+109,100
| +128% | +$815K | ﹤0.01% | 5917 |
|
|
2025
Q3 | $266K | Buy |
85,500
+58,100
| +212% | +$154K | ﹤0.01% | 10398 |
|
|
2025
Q2 | $58.6K | Buy |
+27,400
| New | +$44.3K | ﹤0.01% | 12063 |
|
|
2025
Q1 | – | Sell |
-25,000
| Closed | -$54.8K | – | 13554 |
|
|
2024
Q4 | $54.8K | Buy |
25,000
+15,000
| +150% | +$34K | ﹤0.01% | 11639 |
|
|
2024
Q3 | $21.8K | Sell |
10,000
-181,700
| -95% | -$418K | ﹤0.01% | 11614 |
|
|
2024
Q2 | $443K | Buy |
191,700
+46,600
| +32% | +$194K | ﹤0.01% | 8559 |
|
|
2024
Q1 | $798K | Buy |
145,100
+72,600
| +100% | +$332K | ﹤0.01% | 7412 |
|
|
2023
Q4 | $179K | Sell |
72,500
-48,300
| -40% | -$459K | ﹤0.01% | 10794 |
|
|
2023
Q3 | $4.2M | Buy |
120,800
+85,500
| +242% | +$2.96M | ﹤0.01% | 3834 |
|
|
2023
Q2 | $1.16M | Sell |
35,300
-41,900
| -54% | -$1.44M | ﹤0.01% | 6342 |
|
|
2023
Q1 | $2.59M | Buy |
+77,200
| New | +$3M | ﹤0.01% | 4619 |
|
|
2022
Q4 | – | Sell |
-26,400
| Closed | -$922K | – | 13799 |
|
|
2022
Q3 | $922K | Buy |
+26,400
| New | +$585K | ﹤0.01% | 6837 |
|
Other funds holding VTYX
Jeff Yass's VTYX Position: Q1 2026 in Review
Jeff Yass sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 1,118,275 shares — an estimated $10.1M sold.
Jeff Yass first reported a position in VTYX in Q3 2022 and held it in 12 quarters. The position peaked at $10.1M in Q4 2025. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- Jeff Yass reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- Jeff Yass sold 1,118,275 Ventyx Biosciences shares in Q1 2026, an estimated $10.1M.
- Jeff Yass first reported a position in Ventyx Biosciences in Q3 2022 and held it in 12 quarters.
- Jeff Yass's Ventyx Biosciences position peaked at $10.1M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.